1. A 74-year-old man with a history of ventricular tachycardia has been on amiodarone 200 mg daily for 6 years. He presents with a 2-month history of progressive exertional dyspnea, dry cough, and low-grade fever. Chest X-ray shows bilateral interstitial infiltrates. He has no prior history of heart failure or pulmonary disease. His echocardiogram shows preserved EF at 58% and no new wall motion abnormalities. Which of the following represents the most appropriate next steps in management?
A) Increase the furosemide dose and add spironolactone: the bilateral infiltrates most likely represent new-onset heart failure from amiodarone-induced cardiomyopathy, and diuresis should begin before pulmonary function testing
B) Obtain sputum cultures and start broad-spectrum antibiotics: the low-grade fever with bilateral infiltrates most likely represents community-acquired pneumonia, and amiodarone should be continued while awaiting culture results
C) Refer for bronchoscopy as the first step, transbronchial biopsy demonstrating foamy macrophages is required to confirm amiodarone pulmonary toxicity before any management decisions can be made
D) Check TSH and free T4: the bilateral infiltrates and dyspnea most likely represent amiodarone-induced hyperthyroidism causing high-output cardiac failure with pulmonary edema
E) Obtain high-resolution CT of the chest, discontinue amiodarone, and initiate corticosteroids if toxicity is confirmed: this presentation is consistent with amiodarone pulmonary toxicity, the most serious organ toxicity of the drug, which requires drug discontinuation and immunosuppression in severe cases
ANSWER: E
Rationale:
This presentation, progressive dyspnea, dry cough, low-grade fever, and bilateral interstitial infiltrates after 6 years of amiodarone therapy with a preserved EF excluding heart failure, is the classic syndrome of amiodarone pulmonary toxicity (interstitial pneumonitis). The appropriate management is high-resolution CT of the chest to characterize the pattern and extent (typically ground-glass opacification and interstitial thickening in a peripheral distribution), discontinuation of amiodarone, and initiation of corticosteroids in severe or progressive cases. Amiodarone's 40 to 55 day half-life means drug levels decline slowly after discontinuation.
Option A: Option A incorrectly attributes the infiltrates to amiodarone-induced cardiomyopathy causing heart failure, amiodarone does not cause cardiomyopathy, and the preserved EF and absence of prior HF make heart failure unlikely; diuresis is not the appropriate first step.
Option B: Option B incorrectly prioritizes infectious workup, while pneumonia should be in the differential, the clinical context of 6 years of amiodarone therapy makes drug toxicity the primary concern, and continuing amiodarone while awaiting cultures would delay necessary drug discontinuation.
Option C: Option C overstates the role of bronchoscopy, while bronchoscopy may be performed in uncertain cases, foamy macrophages on biopsy are not required before initiating management; the clinical and CT findings are sufficient to act on.
Option D: Option D incorrectly prioritizes thyroid evaluation, amiodarone thyrotoxicosis can cause high-output failure, but the preserved EF, absence of tachycardia, and bilateral interstitial infiltrates point to pulmonary toxicity, not thyroid-driven pulmonary edema.
2. A 66-year-old woman with heart failure with reduced ejection fraction (EF 32%) and atrial fibrillation is maintained on dofetilide 250 mcg twice daily (dose-adjusted for CrCl 48 mL/min). She develops a urinary tract infection and her primary care physician calls to ask about antibiotic options. Her urine culture shows trimethoprim-susceptible Escherichia coli. Which of the following correctly advises on antibiotic selection?
A) Trimethoprim-sulfamethoxazole is the preferred choice: it is the most effective agent for susceptible urinary E. coli and the dofetilide interaction is only clinically significant at full trimethoprim doses above 320 mg twice daily, which are not used for uncomplicated urinary tract infection
B) Trimethoprim-sulfamethoxazole is acceptable provided the QTc is rechecked within 48 hours of starting and dofetilide is held for the duration of the antibiotic course: the interaction is pharmacodynamic (additive QT prolongation) and is reversible with temporary dofetilide discontinuation
C) Trimethoprim and trimethoprim-sulfamethoxazole are contraindicated with dofetilide, trimethoprim inhibits renal OCT2, reducing dofetilide tubular secretion and raising plasma levels; an appropriate alternative for this susceptible infection is nitrofurantoin or fosfomycin, neither of which inhibits OCT2
D) Ciprofloxacin is the safest choice, fluoroquinolones do not interact with dofetilide pharmacokinetically, and ciprofoxacin's QT-prolonging effect is insufficient to cause torsades de pointes at standard oral doses in patients without pre-existing QT prolongation
E) Any oral antibiotic is acceptable with dofetilide: the OCT2 interaction with trimethoprim applies only to IV formulations at doses used for Pneumocystis pneumonia treatment, not to the low oral doses used for urinary tract infection
ANSWER: C
Rationale:
Trimethoprim is an explicit OCT2 inhibitor listed as a contraindicated combination in dofetilide prescribing guidelines, alongside verapamil, cimetidine, ketoconazole, and megestrol. The interaction is pharmacokinetic: OCT2 inhibition reduces dofetilide renal tubular secretion, causing drug accumulation, amplified QTc prolongation, and substantially elevated TdP risk. The contraindication applies to all trimethoprim-containing formulations regardless of dose, trimethoprim-sulfamethoxazole at standard UTI doses contains sufficient trimethoprim to produce clinically significant OCT2 inhibition. Appropriate alternatives for this susceptible E. coli UTI include nitrofurantoin (macrocrystals 100 mg twice daily for 5 to 7 days) or fosfomycin (3 g single oral dose), neither inhibits OCT2 or raises dofetilide levels.
Option A: Option A incorrectly states that the interaction is only significant at doses above 320 mg twice daily: the OCT2 interaction occurs at standard UTI trimethoprim doses and the contraindication is absolute regardless of dose.
Option B: Option B incorrectly characterizes the interaction as pharmacodynamic additive QT prolongation and proposes dofetilide discontinuation as a management strategy: the interaction is pharmacokinetic (raising dofetilide levels via OCT2), and temporary dofetilide discontinuation does not eliminate the risk during co-administration; the correct approach is to avoid trimethoprim entirely.
Option D: Option D incorrectly recommends ciprofloxacin as safe, fluoroquinolones including ciprofloxacin prolong the QT interval independently and should be avoided with dofetilide given their additive proarrhythmic potential.
Option E: Option E incorrectly states that the OCT2 interaction is limited to IV trimethoprim at high doses: the interaction occurs with oral trimethoprim at standard doses and the prescribing contraindication does not specify a dose threshold.
3. A 70-year-old man has been on amiodarone 200 mg daily for 4 years for ventricular arrhythmia. He develops thyrotoxicosis with TSH suppressed to 0.01 mU/L and markedly elevated free T4. Thyroid ultrasound shows a normal-sized gland with no nodules and reduced Doppler vascularity. Radioiodine uptake is low. His endocrinologist diagnoses amiodarone-induced thyrotoxicosis type 2. Which of the following represents the correct first-line treatment and explains why it differs from the treatment of type 1?
A) Oral prednisolone 40 mg daily, amiodarone-induced thyrotoxicosis type 2 is a destructive thyroiditis in which direct amiodarone toxicity causes follicular cell damage and unregulated hormone release; thionamides are ineffective because there is no active hormone synthesis to block, making corticosteroids the appropriate treatment
B) Carbimazole 20 mg twice daily, type 2 amiodarone-induced thyrotoxicosis is characterized by autonomous iodine-driven hormone synthesis in damaged follicular cells, and thionamides suppress this synthesis as effectively as in type 1
C) Potassium iodide loading: the high iodine content of amiodarone paradoxically creates an iodide excess that can be overcome by saturating thyroid iodide uptake with exogenous iodide, inducing the Wolff-Chaikoff effect and halting hormone synthesis in both type 1 and type 2
D) Propylthiouracil 300 mg three times daily combined with potassium iodide, type 2 thyrotoxicosis requires a combined approach because the destructive component releases preformed hormone while new synthesis continues simultaneously and must be blocked by two separate mechanisms
E) Beta-blockade alone with propranolol 40 mg three times daily, type 2 amiodarone-induced thyrotoxicosis is self-limiting because the hormone release from follicular destruction is finite; symptomatic control with beta-blockade while awaiting spontaneous resolution is sufficient without specific thyroid-directed therapy
ANSWER: A
Rationale:
Amiodarone-induced thyrotoxicosis type 2 (AIT-2) is a destructive thyroiditis, direct amiodarone (and desethylamiodarone) toxicity damages thyroid follicular cells, causing unregulated release of preformed thyroid hormones without new synthesis. The hallmarks are a normal or reduced-size gland, absent or low Doppler vascularity, and low radioiodine uptake (reflecting suppressed or absent thyroid function, not active synthesis). Because there is no ongoing hormone synthesis to block, thionamides (carbimazole, propylthiouracil) are largely ineffective. Corticosteroids, typically prednisolone 40 mg daily, are the treatment of choice: they reduce thyroid inflammation, suppress the destructive process, and accelerate resolution. AIT type 1, by contrast, occurs in abnormal glands (nodular or with latent Graves disease) driven by iodine-induced autonomous synthesis, and responds to thionamides.
Option B: Option B incorrectly prescribes carbimazole, thionamides block thyroid hormone synthesis, but in AIT-2 the excess hormone comes from follicular cell destruction (preformed hormone release), not active synthesis; carbimazole is ineffective.
Option C: Option C incorrectly proposes potassium iodide loading, KI is not standard therapy for AIT-2 and does not address the destructive pathophysiology; the Wolff-Chaikoff effect requires functioning follicular cells capable of organification, which are damaged in type 2.
Option D: Option D incorrectly combines propylthiouracil and KI: this approach applies to preparation for thyroid surgery or radioiodine in Graves disease, not to AIT-2 where the problem is hormone release from damaged, not hyperactive, follicles.
Option E: Option E incorrectly states that AIT-2 is reliably self-limiting and requires only beta-blockade, while milder cases may eventually resolve, the thyrotoxicosis in AIT-2 can be severe and prolonged; corticosteroids are required to suppress the destructive inflammatory process.
4. A 71-year-old woman with atrial fibrillation is on day 2 of sotalol initiation (80 mg twice daily) when telemetry shows three self-terminating episodes of polymorphic ventricular tachycardia with a twisting QRS axis, each preceded by a long pause following a premature ventricular beat. Her QTc has risen from 434 ms at baseline to 528 ms. Serum potassium is 3.0 mEq/L and magnesium is 1.4 mg/dL. What is the correct immediate management?
A) Increase the sotalol dose to 120 mg twice daily to shorten the RR interval through enhanced beta-blockade, reducing the pause duration that is triggering each TdP episode
B) Discontinue sotalol immediately, administer IV magnesium sulfate 2 g over 1 to 2 minutes, aggressively correct hypokalemia (target K+ above 4.0 mEq/L) and hypomagnesemia, and initiate temporary transvenous overdrive pacing at 90 to 110 bpm if TdP remains recurrent
C) Reduce sotalol to 40 mg twice daily, administer oral potassium chloride 40 mEq, and continue telemetry, at the lower dose QTc will shorten within 12 hours and the electrolyte correction will provide sufficient protection against further TdP episodes
D) Administer IV amiodarone 150 mg over 10 minutes to provide counter-regulatory multi-channel blockade and suppress the triggered activity driving TdP, then discontinue sotalol and continue amiodarone for rhythm maintenance
E) Administer IV adenosine 6 mg to terminate the re-entrant circuit, place a temporary transvenous pacemaker at rate 70 bpm, and continue sotalol at the current dose with twice-daily QTc monitoring
ANSWER: B
Rationale:
This is pause-dependent TdP occurring during sotalol initiation in the context of significant hypokalemia and hypomagnesemia, precisely the electrolyte conditions that most amplify IKr-blocking drug effects. Sotalol must be discontinued immediately: the QTc of 528 ms has exceeded the 500 ms stopping criterion and TdP is occurring. IV magnesium sulfate 2 g is the first-line pharmacologic treatment regardless of serum magnesium level. Aggressive electrolyte correction is essential, hypokalemia at 3.0 mEq/L and hypomagnesemia at 1.4 mg/dL both amplify the IKr blockade-driven APD prolongation; target potassium above 4.0 mEq/L and magnesium above 2.0 mg/dL. Because TdP is pause-dependent (triggered by the post-extrasystolic pause), temporary transvenous overdrive pacing at 90 to 110 bpm eliminates the pauses that generate EADs, providing definitive short-term rhythm control. Option A is dangerous: increasing sotalol increases both IKr blockade and QT prolongation: this would dramatically worsen TdP risk and is the opposite of appropriate management.
Option C: Option C is incorrect: the QTc of 528 ms has already exceeded the mandatory stopping criterion of 500 ms; sotalol must be discontinued, not reduced, and oral electrolyte correction is too slow for this acute setting.
Option D: Option D is incorrect: amiodarone is a QT-prolonging agent and would worsen the proarrhythmic substrate; IV amiodarone is contraindicated in the setting of active TdP from QT prolongation.
Option E: Option E is incorrect: adenosine is ineffective for ventricular arrhythmias (TdP is not an AV nodal tachycardia), pacing at 70 bpm would not eliminate the pauses at the rates seen here, and continuing sotalol with a QTc of 528 ms and active TdP is absolutely contraindicated.
5. A 62-year-old woman with paroxysmal atrial fibrillation and no structural heart disease is maintained on dronedarone 400 mg twice daily. She presents with a community-acquired pneumonia and her pulmonologist prescribes clarithromycin 500 mg twice daily. The pharmacist flags this combination. Which of the following correctly identifies the mechanism and magnitude of this drug interaction and recommends appropriate management?
A) The interaction is pharmacodynamic, clarithromycin and dronedarone both block IKr, and combined use produces additive QT prolongation with a clinically manageable torsades de pointes risk; reducing dronedarone to 200 mg twice daily for the duration of the antibiotic course is appropriate
B) The interaction is minimal, clarithromycin's CYP3A4 inhibition affects dronedarone metabolism only at doses above 1 g twice daily; at standard 500 mg twice daily dosing, no clinically significant dronedarone level elevation occurs and no dose adjustment is needed
C) The interaction is through P-glycoprotein induction by clarithromycin, which increases dronedarone renal elimination and reduces plasma dronedarone levels: this may reduce antiarrhythmic efficacy and a temporary dose increase to 600 mg twice daily is appropriate
D) Clarithromycin is a potent CYP3A4 inhibitor that raises dronedarone plasma levels by approximately 25-fold: this combination is explicitly contraindicated in dronedarone prescribing guidelines; clarithromycin must be substituted with an antibiotic that does not significantly inhibit CYP3A4, such as amoxicillin or doxycycline
E) The interaction is bidirectional, dronedarone inhibits CYP3A4 and raises clarithromycin levels while clarithromycin inhibits CYP3A4 and raises dronedarone levels; both drugs should be reduced to half their standard doses and QTc monitored daily
ANSWER: D
Rationale:
Dronedarone is primarily metabolized by CYP3A4. Clarithromycin is a potent CYP3A4 inhibitor, co-administration raises dronedarone plasma concentrations by approximately 25-fold, creating an extreme risk of dronedarone toxicity including severe bradycardia, AV block, and QT-prolongation-mediated TdP. This combination is explicitly contraindicated in dronedarone prescribing guidelines, alongside other potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir. The appropriate management is to substitute clarithromycin with an antibiotic that provides adequate pneumonia coverage without significant CYP3A4 inhibition, amoxicillin-clavulanate or doxycycline are appropriate alternatives depending on the organism and severity.
Option A: Option A incorrectly characterizes the interaction as pharmacodynamic additive QT prolongation manageable by dose reduction: the interaction is a pharmacokinetic one producing a 25-fold rise in dronedarone levels, which no dose reduction adequately mitigates; the combination must be avoided.
Option B: Option B incorrectly states that the interaction is only significant at clarithromycin doses above 1 g twice daily, clarithromycin is a potent CYP3A4 inhibitor at standard clinical doses; the 25-fold dronedarone level increase occurs at standard 500 mg twice daily dosing.
Option C: Option C incorrectly attributes the interaction to P-glycoprotein induction reducing dronedarone levels, clarithromycin inhibits both CYP3A4 and P-glycoprotein; both effects raise dronedarone levels, not reduce them.
Option E: Option E incorrectly proposes halving both drugs as a management strategy: the magnitude of CYP3A4 inhibition by clarithromycin is such that dose halving does not adequately reduce the dronedarone level elevation, and the combination must be avoided entirely.
6. A 63-year-old man with ischemic cardiomyopathy (EF 30%) and an implantable cardioverter-defibrillator is admitted with frequent ICD shocks over the past 48 hours. Telemetry confirms recurrent sustained monomorphic ventricular tachycardia at 162 bpm between shock therapies; the patient is hemodynamically stable between episodes. His current medications include carvedilol, sacubitril-valsartan, and eplerenone. Which antiarrhythmic agent is most appropriate to reduce VT burden and ICD shock frequency?
A) IV amiodarone loading followed by oral maintenance, amiodarone is the first-line agent for VT storm in structural heart disease, is safe in HFrEF, and its multi-channel mechanism provides broad efficacy against refractory ventricular arrhythmias; OPTIC trial data support its use as an adjunct to ICD therapy to reduce shock burden
B) IV flecainide 2 mg/kg over 10 minutes: Class Ic agents produce rapid VT termination through potent sodium channel blockade and are preferred in ICD recipients because their rate-dependent sodium channel effects specifically suppress the fast ventricular rates during VT
C) IV lidocaine 1.5 mg/kg followed by infusion, lidocaine is the preferred agent for VT in HFrEF because it shortens APD without QT prolongation, avoids the organ toxicity of amiodarone, and the ALPS trial demonstrated lidocaine superiority over amiodarone for VT in structural heart disease
D) IV sotalol 1.5 mg/kg over 5 minutes, sotalol's combined Class II and III mechanism provides superior VT suppression in ICD recipients compared to amiodarone, and the OPTIC trial demonstrated significant reduction in appropriate ICD shocks with IV sotalol as the primary adjunct therapy
E) IV dofetilide 500 mcg as a single slow infusion, dofetilide's pure IKr blockade produces potent VT suppression in HFrEF with a lower organ toxicity burden than amiodarone, and DIAMOND-CHF data support its use for VT storm management in this population
ANSWER: A
Rationale:
Amiodarone is the first-line antiarrhythmic agent for VT storm (recurrent sustained VT) in patients with structural heart disease, including HFrEF. Its multi-channel mechanism (Classes I through IV) provides broad efficacy against sustained ventricular arrhythmias, it does not cause hemodynamic compromise in HFrEF at IV loading doses, and the OPTIC (Optimal Pharmacological Therapy in Cardioverter-Defibrillator Patients) trial demonstrated that amiodarone plus beta-blocker reduced appropriate ICD shocks significantly more than beta-blocker alone or sotalol.
Option B: Option B is incorrect: flecainide and all Class Ic agents are contraindicated in structural heart disease including HFrEF: the CAST trial established increased mortality with Class Ic agents in this population, and their use here would be both contraindicated and potentially life-threatening.
Option C: Option C incorrectly states that the ALPS trial demonstrated lidocaine superiority over amiodarone for VT in structural heart disease, ALPS compared amiodarone and lidocaine to placebo in shock-refractory VF during cardiac arrest; it did not demonstrate lidocaine superiority and both drugs are guideline-supported, but amiodarone remains first-line for stable VT in structural heart disease.
Option D: Option D incorrectly attributes superior VT suppression and OPTIC trial evidence to IV sotalol, OPTIC demonstrated that amiodarone plus beta-blocker outperformed sotalol for shock reduction; sotalol is also generally avoided in HFrEF with EF below 40%.
Option E: Option E incorrectly proposes IV dofetilide for VT storm, dofetilide does not have an approved IV formulation for VT storm management, DIAMOND-CHF established neutral mortality in HFrEF with oral dofetilide for AF, not efficacy for VT suppression.
7. A 58-year-old woman with no structural heart disease undergoes successful pharmacologic cardioversion of recent-onset atrial flutter with IV ibutilide 1 mg. Twenty-two minutes after the infusion ends, she develops a polymorphic wide-complex tachycardia with a twisting QRS axis at 220 bpm. The monitor confirms torsades de pointes. Her blood pressure is 88/54 mmHg. She is conscious but diaphoretic and lightheaded. Which of the following represents the correct immediate management sequence?
A) IV amiodarone 150 mg over 10 minutes, amiodarone provides multi-channel counter-regulation of the IKr-driven APD prolongation responsible for TdP and is the first-line treatment for hemodynamically unstable TdP in the post-ibutilide setting
B) IV magnesium sulfate 2 g over 1 to 2 minutes as first-line, followed immediately by synchronized DC cardioversion if TdP does not terminate spontaneously within 60 seconds, if TdP terminates and recurs, IV isoproterenol infusion can be used to increase heart rate and suppress the pauses triggering re-initiation
C) Immediate unsynchronized DC cardioversion at 200 J, hemodynamic compromise with blood pressure of 88/54 mmHg in the setting of active torsades de pointes at 220 bpm requires immediate electrical cardioversion without delay for pharmacologic therapy
D) IV lidocaine 1.5 mg/kg, lidocaine shortens APD by blocking late inward sodium current and is the preferred treatment for post-ibutilide TdP because it directly opposes the slow inward sodium current mechanism by which ibutilide prolongs APD
E) IV adenosine 6 mg rapid bolus, ibutilide-induced TdP is a form of triggered re-entrant tachycardia with AV nodal dependence, and adenosine produces transient AV block that interrupts the re-entrant circuit and terminates TdP
ANSWER: C
Rationale:
This patient has hemodynamically compromised TdP: a blood pressure of 88/54 mmHg with symptoms of hypoperfusion (diaphoresis, lightheadedness) at a ventricular rate of 220 bpm. When TdP produces hemodynamic compromise, immediate unsynchronized DC cardioversion is the correct intervention. Unlike stable, self-terminating TdP where magnesium is the pharmacologic first-line, hemodynamically unstable TdP requires immediate electrical termination. Synchronization is typically not used for TdP because the irregular, polymorphic QRS makes reliable synchronization unreliable and dangerous, unsynchronized shock is appropriate. After cardioversion, IV magnesium sulfate should be administered to raise the threshold for EAD formation and reduce the risk of recurrence. Option B correctly identifies IV magnesium as first-line for stable TdP and the appropriate subsequent steps, but this sequence is not appropriate when the patient is already hemodynamically compromised: a blood pressure of 88/54 mmHg with TdP at 220 bpm requires immediate cardioversion, not a 60-second wait for magnesium to act.
Option A: Option A is incorrect: amiodarone prolongs QT and would worsen the proarrhythmic substrate driving TdP: it is contraindicated in this setting.
Option D: Option D is incorrect: while lidocaine may theoretically shorten APD, it is not the established treatment for hemodynamically compromised TdP, immediate cardioversion takes priority; and lidocaine's mechanism does not specifically oppose ibutilide's slow inward sodium current activation at standard doses.
Option E: Option E is incorrect: TdP is not AV nodal-dependent and adenosine is not effective for ventricular arrhythmias; applying adenosine to TdP at 220 bpm with hemodynamic compromise is inappropriate and would waste critical time.
8. A 67-year-old man with HFrEF (EF 33%) and persistent atrial fibrillation is on day 1 of dofetilide initiation (500 mcg twice daily, CrCl 68 mL/min). His baseline QTc was 428 ms. Two hours after the first morning dose, his QTc measures 508 ms. He is asymptomatic, in sinus rhythm after converting overnight, and his electrolytes are normal. What is the correct action per the mandatory monitoring protocol?
A) Continue dofetilide at 500 mcg twice daily and recheck QTc in 6 hours: a QTc of 508 ms is within the expected range of QT prolongation during dofetilide initiation in HFrEF and does not require dose adjustment in the absence of symptoms or arrhythmia
B) Discontinue dofetilide immediately and do not rechallenge: a QTc above 500 ms at any measurement during initiation represents a mandatory permanent contraindication to dofetilide in this patient, and no dose reduction protocol exists
C) Administer IV magnesium sulfate 2 g prophylactically and continue dofetilide at the current dose, prophylactic magnesium prevents torsades de pointes during dofetilide initiation and allows continuation at full dose when QTc rises above 500 ms
D) Notify the attending and continue monitoring: a QTc of 508 ms requires documentation and physician review but no immediate dose change, as the stopping criterion for dofetilide is QTc exceeding 550 ms, not 500 ms
E) Reduce the dofetilide dose to the next lower tier (250 mcg twice daily) and recheck QTc 2 to 3 hours after the next dose, if QTc remains above 500 ms at the lower dose, dofetilide must be discontinued; if QTc falls below 500 ms, the lower dose can be continued
ANSWER: E
Rationale:
The mandatory dofetilide initiation protocol requires QTc measurement 2 to 3 hours after each dose. If QTc exceeds 500 ms (or 550 ms in patients with bundle branch block), the dose must be reduced to the next lower tier, in this patient, from 500 mcg twice daily to 250 mcg twice daily. The QTc must then be rechecked 2 to 3 hours after the next dose at the lower dose: if QTc remains above 500 ms at 250 mcg twice daily, dofetilide must be discontinued; if QTc falls below 500 ms, therapy can continue at 250 mcg twice daily. This step-down approach allows continued therapy at a safer dose level rather than mandatory immediate discontinuation at first QTc crossing of 500 ms.
Option A: Option A is incorrect: a QTc of 508 ms has crossed the 500 ms action threshold and requires dose reduction per the initiation protocol, continuing at the same dose without action is not appropriate.
Option B: Option B incorrectly states that any QTc above 500 ms is a permanent contraindication: the protocol specifies dose reduction as the first step; permanent discontinuation is required only if QTc remains above 500 ms at the lowest dose tier or if the patient develops TdP.
Option C: Option C incorrectly proposes prophylactic magnesium as a substitute for dose adjustment, magnesium does not lower the QTc and cannot be used to permit continuation at a dose that has produced QTc exceeding 500 ms.
Option D: Option D incorrectly states that the stopping criterion is QTc exceeding 550 ms: the 500 ms threshold (in patients with normal intraventricular conduction) is the action threshold for dose reduction, not 550 ms.
9. A 75-year-old man with atrial fibrillation has been stable on warfarin (INR 2.3) and amiodarone 200 mg daily for 3 years. His pulmonologist diagnoses amiodarone pulmonary toxicity and recommends amiodarone discontinuation. The patient asks whether he can stop monitoring his INR frequently once amiodarone is stopped. Which of the following correctly advises on warfarin management through and after amiodarone discontinuation?
A) INR monitoring can be reduced to monthly once amiodarone is discontinued, after stopping amiodarone, its CYP2C9 inhibitory effect resolves within 1 to 2 weeks as the drug is cleared from plasma, and warfarin metabolism rapidly normalizes to its pre-amiodarone rate
B) INR must continue to be monitored closely for several months after amiodarone discontinuation, amiodarone's half-life of 40 to 55 days means tissue levels decline very slowly, and CYP2C9 inhibition persists for weeks to months after the last dose; as amiodarone clears, warfarin metabolism gradually recovers and the INR will progressively fall, potentially dropping below the therapeutic range and increasing stroke risk if the warfarin dose is not adjusted upward
C) Warfarin should be switched to a direct oral anticoagulant at amiodarone discontinuation: the unpredictable rate of CYP2C9 recovery makes INR monitoring unreliable during the washout period, and DOACs are preferred because their anticoagulant effect is not affected by CYP2C9 activity
D) INR monitoring can stop entirely once amiodarone is discontinued: the CYP2C9 inhibitory effect of amiodarone is reversed within 72 hours of the last dose as the drug is rapidly metabolized, and warfarin will return to its pre-interaction pharmacokinetics within the first week
E) The warfarin dose should be increased by 25% at amiodarone discontinuation to preemptively compensate for the loss of CYP2C9 inhibition, without this increase, the INR will fall below therapeutic range within 2 weeks of stopping amiodarone
ANSWER: B
Rationale:
Amiodarone's half-life of 40 to 55 days and volume of distribution of 60 to 100 L/kg mean that tissue concentrations decline very slowly after the last dose, clinically meaningful amiodarone levels may persist for 6 to 12 months after discontinuation. CYP2C9 inhibition, which has been reducing warfarin metabolism and maintaining an elevated INR, wanes gradually as amiodarone clears. The warfarin dose that was appropriate during amiodarone therapy (reduced by one-third to one-half) will become insufficient as CYP2C9 inhibition lifts, warfarin metabolism will gradually normalize and the INR will fall. Without close monitoring and warfarin dose adjustment upward as amiodarone clears, the patient's INR may drop below therapeutic range for weeks to months, substantially increasing thromboembolic stroke risk. INR should be checked weekly or more frequently during the amiodarone washout period.
Option A: Option A incorrectly states that CYP2C9 inhibition resolves within 1 to 2 weeks, plasma amiodarone levels fall rapidly after stopping, but tissue levels and the associated CYP2C9 inhibition persist for weeks to months due to amiodarone's extraordinary tissue accumulation.
Option C: Option C is incorrect as an automatic switch to DOAC is not required, warfarin with close INR monitoring during washout is a well-established management approach; switching anticoagulants is a clinical decision, not mandatory.
Option D: Option D is incorrect: amiodarone's CYP2C9 effect does not reverse within 72 hours: this dramatically underestimates the pharmacokinetic persistence driven by the 40 to 55 day half-life.
Option E: Option E incorrectly proposes a single preemptive 25% dose increase: the rate of INR decline during washout is variable and unpredictable; dose adjustments must be guided by serial INR measurements, not by a fixed preemptive increase.
10. A 59-year-old man with paroxysmal atrial fibrillation and no structural heart disease is started on sotalol 80 mg twice daily for rhythm control. His cardiologist explains that he will not need a separate rate control agent because sotalol's beta-blocking activity will control his ventricular rate during any AF breakthrough. Which of the following best evaluates the accuracy of this clinical reasoning?
A) The reasoning is correct, sotalol's l-isomer provides non-selective beta-adrenergic blockade that reliably controls ventricular rate during AF breakthrough at the doses used for rhythm control, eliminating the need for a separate rate control agent in all patients
B) The reasoning is partially correct, sotalol controls ventricular rate adequately at rest through beta-blockade, but does not reliably prevent rapid ventricular responses during exercise or sympathetic activation; a separate rate control agent may be needed in active patients with frequent AF breakthrough
C) The reasoning is incorrect, sotalol is contraindicated as a rate control agent in atrial fibrillation because its IKr-blocking component shortens the AV nodal refractory period and accelerates AV conduction during AF, paradoxically increasing ventricular rates above those seen without treatment
D) The reasoning is flawed, while sotalol's beta-blocking activity does slow AV nodal conduction at rest, sotalol does not provide reliable or adequate ventricular rate control during AF compared to dedicated rate control agents; patients with frequent AF breakthrough on sotalol typically require an additional rate control agent
E) The reasoning is correct only if the sotalol dose is escalated to 160 mg twice daily, at 80 mg twice daily, the Class II component is insufficient for meaningful rate control, but at 160 mg the beta-blocking effect adequately controls the ventricular response during AF breakthrough without an additional agent
ANSWER: D
Rationale:
Sotalol's beta-blocking (Class II) activity does slow AV nodal conduction and can modestly reduce the ventricular rate during AF, but sotalol is not a reliable or adequate rate control agent compared to dedicated AV nodal blocking drugs (beta-blockers at rate control doses, diltiazem, or verapamil). The ventricular rate during AF depends on AV nodal conduction, which is substantially influenced by sympathetic tone, sotalol's non-selective beta-blockade at antiarrhythmic doses provides only partial rate control, particularly during sympathetic activation. Patients with frequent AF breakthrough on sotalol often require an additional rate control agent. The primary purpose of sotalol in this patient is rhythm maintenance through its IKr-blocking Class III effect, and the rate control assumption built into the cardiologist's reasoning is not reliably valid. Option B is closer to correct than A but understates the limitation, sotalol's rate control is unreliable not only during exercise but also at rest with higher sympathetic tone, and the need for a separate agent is not limited to active patients.
Option A: Option A overstates sotalol's rate control reliability: the beta-blockade at standard antiarrhythmic doses does not provide the same degree of rate control as dedicated AV nodal blocking agents, particularly during exercise.
Option C: Option C incorrectly states that sotalol's IKr blockade shortens the AV nodal refractory period and accelerates AV conduction, IKr blockade prolongs refractoriness throughout the heart including the AV node; it does not accelerate AV conduction.
Option E: Option E incorrectly proposes that escalating to 160 mg resolves the rate control limitation, dose escalation increases TdP risk proportionally and does not convert sotalol into a reliable rate control agent equivalent to dedicated AV nodal blockers.
11. A 64-year-old man with coronary artery disease, prior MI 3 years ago, ejection fraction 48%, paroxysmal atrial fibrillation, and creatinine clearance 38 mL/min presents for rhythm control selection. His baseline QTc is 436 ms and he has had no hospitalizations for heart failure. Which of the following correctly identifies the available rhythm control options and excludes those that are contraindicated?
A) Sotalol is contraindicated because his creatinine clearance of 38 mL/min falls below the 40 mL/min threshold; flecainide and propafenone are contraindicated by CAST evidence in post-MI structural heart disease; dronedarone is acceptable (EF preserved, no HFrEF, no permanent AF, no recent decompensation); amiodarone and dofetilide (dose-adjusted for CrCl 20 to 40 mL/min at 125 mcg twice daily with in-hospital initiation) are also appropriate
B) Only amiodarone is appropriate, sotalol is contraindicated renally, Class Ic agents are contraindicated by CAST, dronedarone is contraindicated because prior MI constitutes structural heart disease that meets the ANDROMEDA exclusion, and dofetilide is contraindicated because CrCl below 40 mL/min is below the dofetilide initiation threshold
C) Dronedarone and sotalol are both appropriate, his EF of 48% is above the HFrEF threshold for dronedarone, and sotalol's renal contraindication applies only to patients with CrCl below 30 mL/min; flecainide and propafenone remain contraindicated by CAST
D) Any antiarrhythmic agent is acceptable in this patient: the CAST contraindication applies to patients with active ischemia and ventricular ectopy, not to patients who are 3 years post-MI with preserved EF and no current ischemia
E) Dofetilide is the only appropriate option, his CrCl of 38 mL/min (in the 20 to 40 range requiring 125 mcg twice daily) is the only agent with a renal dose adjustment that permits use below 40 mL/min; amiodarone requires normal renal function and dronedarone is contraindicated in all post-MI patients
ANSWER: A
Rationale:
Working through each agent systematically: Sotalol is contraindicated, CrCl 38 mL/min falls below the 40 mL/min threshold. Flecainide and propafenone are contraindicated, CAST established that Class Ic agents increase mortality in structural heart disease including post-MI, regardless of current EF or ischemic status. Dronedarone is acceptable, his EF of 48% is above the HFrEF concern threshold, he has had no recent decompensation, and his AF is paroxysmal (not permanent); the ANDROMEDA contraindication applies to HFrEF or recently decompensated HF, not to all post-MI patients with preserved EF. Dofetilide is acceptable, CrCl 38 mL/min falls in the 20 to 40 mL/min range, requiring dose reduction to 125 mcg twice daily with mandatory in-hospital initiation. Amiodarone is acceptable: it requires no renal dose adjustment and is appropriate in structural heart disease.
Option B: Option B incorrectly excludes dronedarone as contraindicated by ANDROMEDA in all post-MI patients, ANDROMEDA contraindicated dronedarone in HFrEF and recently decompensated HF, not in all post-MI patients with preserved EF; and incorrectly states that CrCl below 40 mL/min is the dofetilide contraindication threshold: the dofetilide contraindication threshold is CrCl below 20 mL/min.
Option C: Option C incorrectly states that sotalol's renal contraindication applies only below 30 mL/min: the established threshold is below 40 mL/min.
Option D: Option D incorrectly states that CAST applies only to patients with active ischemia and ventricular ectopy: the contraindication applies to all structural heart disease with LV dysfunction, not only to patients with active ischemia.
Option E: Option E incorrectly states that amiodarone requires normal renal function, amiodarone is hepatically metabolized with no renal dose adjustment required, and incorrectly states dronedarone is contraindicated in all post-MI patients, which overstates the ANDROMEDA contraindication.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.